DEF: Septerna 2026 Annual Meeting Proxy Statement

Septerna, Inc. announces its 2026 Annual Meeting of Stockholders to be held virtually on June 26, 2026.

Summary

• The 2026 Annual Meeting of Stockholders will be held virtually on June 26, 2026, at 2:00 p.m. Pacific Time.
• Stockholders of record as of April 29, 2026, are entitled to vote.
• Proposal 1: Election of two Class II directors, Jake Simson, Ph.D. and Shalini Sharp, M.B.A., to serve until the 2029 Annual Meeting.
• Proposal 2: Ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• The company is an emerging growth company and is utilizing the Notice and Access approach for proxy materials.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing for an annual meeting, reflecting standard corporate governance practices without significant strategic shifts or controversial proposals.

Positives

• Virtual-only meeting format enhances stockholder access and participation from any location.
• The company has established a Research and Development Committee to oversee scientific and clinical strategy.
• The board maintains a separation between the roles of Chairman and Chief Executive Officer to improve governance.
• The company has adopted a compensation recovery policy (clawback) in accordance with SEC and Nasdaq rules.

Negatives

• The company is an emerging growth company, which allows for reduced public company reporting requirements.
• The board is divided into three classes with staggered terms, which may limit the ability of stockholders to change the board composition quickly.

Risks

• Risks related to financial condition, research and development activities, operations, strategic direction, cybersecurity, and intellectual property.
• Potential for future restatements of financial statements leading to the application of the compensation recovery policy.
• Dependence on key personnel and the ability to attract and retain qualified scientific and executive talent.

Future Outlook

The company continues to focus on its research and development pipeline and intends to maintain its status as an emerging growth company until it meets specific financial or market thresholds.

Management Comments

• The board believes the virtual-only meeting format will give stockholders the opportunity to participate fully and equally.
• The board recommends a vote FOR the election of the two nominees for Class II directors and FOR the ratification of the appointment of the independent registered public accounting firm.

Industry Context

StockSavvy.ai notes that Septerna's governance structure, including the use of staggered boards and the 'emerging growth company' designation, is standard for recently public biotechnology firms aiming to focus resources on R&D while maintaining control during early-stage development.

Comparison to Industry Standards

• The use of a virtual-only meeting format is increasingly common among Nasdaq-listed biotechnology companies to reduce costs and improve accessibility.
• The board's committee structure, including the addition of a dedicated Research and Development Committee, aligns with best practices for clinical-stage biopharmaceutical companies.
• The compensation recovery policy is in full compliance with current SEC and Nasdaq mandates.

Management Changes

Corporate Governance

Legal Proceedings

• None disclosed.

Related Party Transactions

• Consulting services provided by Third Rock Ventures, including services of Dr. Ezekowitz.
• Historical financing transactions involving entities affiliated with Third Rock Ventures, RA Capital, and Samsara BioCapital.

Stakeholder Impact

• Shareholders are requested to vote on director elections and auditor ratification.
• Employees and consultants are subject to the company's insider trading and compensation recovery policies.

Next Steps

• Hold the 2026 Annual Meeting of Stockholders on June 26, 2026.
• File a Form 8-K with the SEC within four business days following the meeting to announce final voting results.

Key Dates

Keywords

Septerna, Proxy Statement, Annual Meeting, Biotechnology, Corporate Governance, SEC Filing, Board of Directors